Alternative Investment Funds
United States
12 September 2024
Specializing in complex private placements, spin-offs, and senior unsecured notes offerings, Dechert LLP has a strong track record of representing sovereign issuers and financial sponsors across domestic and international jurisdictions. The firm is especially active in the healthcare, finance, and manufacturing fields, with Boston-based Thomas Friedmann routinely acting on behalf of investment banks and asset managers. From Washington DC, Harry Pangas is knowledgeable in joint ventures, New York’s David Rosenthal is a venture capital expert, while in Philadelphia, Stephen Leitzell focuses on cross-border M&A.
Legal 500 Editorial commentary
Key clients
- Aquestive Therapeutics
- B&G Foods
- Bain Capital Specialty Finance
- BC Partners
- BioAtla
- Blackstone
- Business Development Company of America
- Diffusion Therapeutics
- EaglePoint Credit Company
- FS Investment Corporation
Work highlights
Advising Select Medical Holdings Corporation and Concentra Group Holdings Parent, Inc., a subsidiary of Select Medical, in connection with the contemplated spin-off of Concentra from Select Medical.
Represented Crown Holdings, Inc. (“Crown”) in connection with an offering by Crown European Holdings S.A. (the “Issuer”), a subsidiary of the Company, of €600 million of senior unsecured notes due 2030.
Represented Apollo Debt Solutions BDC in its offering of US$650 million in aggregate principal amount of its 6.900% notes due 2029 in a private placement and in connection with its US$600 million 6.70% investment-grade 144A bond offering
Lawyers
Practice head
Thomas Friedmann; Stephen Leitzell; Harry Pangas; Anna Tomczyk
Other key lawyers
David Rosenthal; Eric Siegel; Jay Alicandri; Ian Hartman; Clay Douglas; Matthew Carter; Anna Tomczyk